Regulatory 2026-06-12

IVD competition is shifting toward documented quality systems and validation evidence

As IVD regulatory expectations continue to evolve, buyers are paying closer attention to intended use, validation evidence, batch records, stability data and post-market traceability.

Editorial news image of laboratory staff reviewing rapid-test validation records and quality documents
Quality-system competition is about traceable, auditable and explainable validation evidence.

Real industry background

FDA’s QMSR final rule further harmonizes medical-device quality-system requirements with ISO 13485:2016. Regulatory paths differ by market, but the common direction is clear: customers want documented, traceable and auditable quality systems.

From sample approval to file readiness

Customers no longer review only sample performance. They also examine design records, performance verification, stability data, batch records, COA, labels, IFU, complaint handling and change control. Missing files slow registration and long-term purchasing.

OEM/ODM audit focus

For OEM/ODM projects, buyers expect suppliers to explain intended use, sample applicability, release criteria, lot-to-lot consistency and post-market feedback loops. Quality systems are now part of commercial negotiation.

Safheal perspective

Safheal product pages, downloads, certificates and news should reduce generic claims and show credible images, formal files, downloadable documents and clear technical descriptions. This lets customers treat the website as part of supplier qualification.

Trust comes from credible scenes, validation files, certificates, downloads and consistent quality language, not from simply saying “we are professional”.

Official reference

FDA - Quality Management System Regulation final rule